Inequitable Conduct Ruling Survives Sanofi Fed. Circ. Appeal

Law360, New York (April 9, 2012, 5:04 PM EDT) -- A decision that two patents for Sanofi-Aventis SA's lucrative cancer drug Taxotere were unenforceable stands up even under the rigorous standard for proving inequitable conduct in patent cases that the Federal Circuit adopted last May, the appeals court said Monday.

A three-judge Federal Circuit panel issued a precedential opinion that rejected Aventis Pharma SA and Sanofi-Aventis U.S. LLC's challenge to a Delaware court's decision that the two Taxotere-related patents were invalid, in addition to being unenforceable due to inequitable conduct.

The Federal Circuit's May ruling in...
To view the full article, register now.